Polycystic kidney disease

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 28, 2023
Momentum, Hyperparathyroidism, Diabetes, Safety, SRL, Innovation, Volunteering, Octreotide, Congenital hyperinsulinism, Research, Clinical trial, FDA, Investment, Patient, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Trial of the century, MAD, MHRA, ACTH, Glomus tumor, Congenital adrenal hyperplasia, Sequoyah, SAN, Polycystic kidney disease, Medicines and Healthcare products Regulatory Agency, MAA, Pharmacodynamics, Graves' ophthalmopathy, Adrenocorticotropic hormone, Food, DSM-IV codes, Carcinoid syndrome, Acromegaly, Health care, Risk management, Pharmaceutical industry, Cryptocurrency, Pharmacokinetics

Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024

Key Points: 
  • Pending a successful outcome from the PATHFNDR studies, an NDA submission in acromegaly is expected in 2024
    SAN DIEGO, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and year ended December 31, 2022.
  • PATHFNDR-2 is the second placebo-controlled Phase 3 clinical study of oral paltusotine in participants with acromegaly.
  • Enrollment is ongoing in the study and the company is aggressively navigating prolonged pandemic-related and geopolitical disruptions in certain key study regions.
  • In April 2022, Crinetics successfully completed an underwritten follow-on offering of its common stock, raising gross proceeds of approximately $125 million.

BALTIMORE PKD RESEARCH AND CLINICAL CORE CENTER RECEIVES PRESTIGIOUS 'CENTER OF EXCELLENCE' DESIGNATION FROM PKD FOUNDATION

Retrieved on: 
Friday, February 24, 2023
Pain management, University, MD, Dialysis, National Intrepid Center of Excellence, Medical Affairs Bureau, Joan, PKD Foundation, Research, Travel, FDA, University of Maryland Medical Center, Radiology, Patient, Element, Genetics, University of Maryland, College Park, DSM-IV codes, University of Maryland School of Medicine, Cyst, Polycystic kidney disease, PKD, Maryland School, Center of excellence, Education, Physician, Kidney failure, Pharmaceutical industry, Nursing, Nephrology, ADPKD, Medicine

BALTIMORE, Feb. 24, 2023 /PRNewswire/ -- The PKD Foundation recently recognized the University of Maryland School of Medicine's (UMSOM) clinical center that treats polycystic kidney disease (PKD) with a highly prestigious "Center of Excellence" designation. The designation recognizes the center as a leader in providing multidisciplinary, comprehensive clinical services for families affected by autosomal dominant polycystic kidney disease (ADPKD), a hereditary condition. It is one of just 28 clinical centers in the U.S. to receive this recognition.

Key Points: 
  • BALTIMORE, Feb. 24, 2023 /PRNewswire/ -- The PKD Foundation recently recognized the University of Maryland School of Medicine's (UMSOM) clinical center that treats polycystic kidney disease (PKD) with a highly prestigious "Center of Excellence" designation.
  • The designation recognizes the center as a leader in providing multidisciplinary, comprehensive clinical services for families affected by autosomal dominant polycystic kidney disease (ADPKD), a hereditary condition.
  • It is one of just 28 clinical centers in the U.S. to receive this recognition.
  • To learn more about multidisciplinary care for patients with PKD at the University of Maryland Medical Center, visit umm.edu/pkd , or contact Karleen Schuhart at (410) 706-3455.

New Paper Highlights Clinical Utility of Natera’s Renasight™ Test in the Management of Kidney Disease

Retrieved on: 
Thursday, February 2, 2023
Health, Genetics, Health Technology, Other Health, Clinical Trials, Biotechnology, DNA, Kidney, Pediatrics, MSCE, Broad Institute, Augusta University Medical Center, Sickle cell disease, ADPKD, Diagnosis, Chronic kidney disease, Boston, Genetic testing, Polycystic kidney disease, National Kidney Foundation, Patient, Hospital, Nephrology, Harvard Medical School, The New England Journal of Medicine, NTRA, Associate, Medicine, Gene, Kidney disease, Manuscript, SCD, Pharmaceutical industry, Nursing, Natera, International Pediatric Nephrology Association, MD

This paper reviews the case of a 16-year-old patient with sickle cell disease (SCD) and kidney cysts.

Key Points: 
  • This paper reviews the case of a 16-year-old patient with sickle cell disease (SCD) and kidney cysts.
  • Natera’s Renasight test, a genetic testing panel that analyzes 385 genes related to kidney disease, was administered to examine whether an additional genetic cause may have been contributing to the patient’s kidney cysts.
  • The test identified genetic variants which led to a diagnosis of autosomal dominant polycystic kidney disease (ADPKD), in addition to the patient’s SCD.
  • Genetic testing is providing care teams with key insights that will better inform disease management and potentially slow disease progression for patients with kidney disease.”
    Chronic kidney disease affects more than 10% of the global population.

Crinetics Pharmaceuticals to Present Corporate and Clinical Update at 41st Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 9, 2023
American Association of Clinical Endocrinologists, Carcinoid syndrome, Malignancy, Congenital hyperinsulinism, Congenital adrenal hyperplasia, Event, Polycystic kidney disease, Injection, Conference, Webcast, Patient, Chronic kidney disease, Drug discovery, Diabetes, SST2, SAN, GPCR, Graves' ophthalmopathy, ACTH, Primary hyperparathyroidism, Hypercalcaemia, Acromegaly, Obesity, Pharmaceutical industry

SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D., founder and chief executive officer of Crinetics, will provide a company update at the 41st Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 9-12, 2023.

Key Points: 
  • SAN DIEGO, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that Scott Struthers, Ph.D. , founder and chief executive officer of Crinetics, will provide a company update at the 41st Annual J.P. Morgan Healthcare Conference, which is taking place in San Francisco, CA from January 9-12, 2023.
  • The presentation will feature an overview of Crinetics’ key priorities and anticipated milestones for 2023.
  • These include:
    The continued advancement of the Phase 3 PATHFNDR-1 and PATHFNDR-2 trials of once-daily oral paltusotine in acromegaly.
  • “Crinetics is entering 2023 with strong momentum and potentially transformative milestones expected over the next year,” said Dr. Struthers.

XORTX Files New Provisional Patent to Diagnose and Treat Individuals Most at Risk of Polycystic Kidney Disease Progression

Retrieved on: 
Tuesday, January 3, 2023
Therapy, Kidney, Research, Patent Cooperation Treaty, Polycystic kidney disease, Laboratory, Risk, Kidney disease, PCT, Patient, Treatment, Polycystic disease, Diagnosis, Patent, Hyperuricemia, Chronic kidney disease, Pharmaceutical industry

This patent is based on key discoveries by XORTX’s independent scientific research partners suggesting that an important diagnostic and therapeutic opportunity exists.

Key Points: 
  • This patent is based on key discoveries by XORTX’s independent scientific research partners suggesting that an important diagnostic and therapeutic opportunity exists.
  • This patent application builds upon new discoveries in polycystic disease and more specifically polycystic kidney disease (“PKD”) and proposes methods of diagnosing the risk associated with aberrant purine metabolism alone, or in combination with hyperuricemia in patients most at risk for accelerated kidney disease progression.
  • Recent discoveries at XORTX and by its independent research laboratories, suggests that certain individuals, most at risk for accelerated kidney disease progression, may be identified, diagnosed, and treated based upon a novel risk profile.
  • This new patent application proposes proprietary diagnostic methods, and potential therapeutic approaches for personalizing the medicines used to treat those most at risk of health consequences of aberrant purine metabolism in cystic kidney diseases.

XORTX Announces Completion of Dosing in XRX-OXY-101 Clinical Study

Retrieved on: 
Monday, December 19, 2022
Clinical, Autosome, Part, ADPKD, Pharmacokinetics, Therapy, Polycystic kidney disease, Kidney disease, Control, FDA, XRX, 2013 Bendigo Women's International (2) – Singles, Marketing, Regulation, Pharmaceutical industry, Chemistry, EU

CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the completion of dosing in the XRX-OXY-101 pharmacokinetics bridging study (the “Study”).

Key Points: 
  • CALGARY, Alberta, Dec. 19, 2022 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat progressive kidney disease, is pleased to announce the completion of dosing in the XRX-OXY-101 pharmacokinetics bridging study (the “Study”).
  • Previously topline results from Part 1 and 2 have been reported in the Company’s press releases of July 13 and August 22, 2022.
  • Plasma sample analysis and topline results from both part 3 and part 4 are expected within the next several weeks.
  • Consolidated topline results from each part are anticipated to be reported in January 2023.

XORTX Announces New Proof of Concept Data in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Retrieved on: 
Thursday, December 8, 2022
Kidney disease, Uric acid, XOI, Kidney failure, Heart, Oxipurinol, TKV, XO, Polycystic kidney disease, Time-invariant system, Fibrosis, Society, University of Colorado Colorado Springs, Nephrology, Therapy, Xanthine oxidase, Creatinine, University, American Society of Nephrology, Pharmaceutical industry, Dietary supplement, Hyperuricemia, ADPKD

If Xanthine oxidase (XO) is expressed in the mouse RC/RC model of polycystic kidney disease (“PKD”), a model for human ADPKD.

Key Points: 
  • If Xanthine oxidase (XO) is expressed in the mouse RC/RC model of polycystic kidney disease (“PKD”), a model for human ADPKD.
  • How increased circulating uric acid concentrations in the cardiovascular system affect kidney weight, heart, inflammatory status and fibrosis.
  • How inhibiting of XO by XORTX’s proprietary XRx-008 formulation of oxypurinol, XORLOTM, attenuates total kidney volume, cyst genesis and cyst growth rate.
  • Pkd1RC/RC mouse develops a slowly progressing polycystic kidney disease with embryonic cyst initiation, present cystic lesions in the liver and elongated primary cilia in collecting ducts.

Eloxx Pharmaceuticals Announces Reverse Stock Split Effective

Retrieved on: 
Thursday, December 1, 2022
Transfer, Proxy, Regulation of tobacco by the U.S. Food and Drug Administration, AST, RMAS, Bangladesh Securities and Exchange Commission, Science, Degenerative disease, Food, RNA, Polycystic kidney disease, Autosome, Patient, Kidney, Royal commission, CF, Fast Track, European Commission, Eukaryotic ribosome, CUSIP, Orphan, Security (finance), Letter, Cancer, Cystic fibrosis, Mutation, FDA, Holding company, Auction

The new CUSIP number for the Companys common stock following the reverse stock split will be 29014R202.

Key Points: 
  • The new CUSIP number for the Companys common stock following the reverse stock split will be 29014R202.
  • As a result of the reverse stock split, every 40 shares of the Companys common stock issued and outstanding will be automatically reclassified into one new share of the Companys common stock.
  • The reverse stock split will not affect the number of authorized shares of common stock or the par value of the common stock.
  • Stockholders who would otherwise be entitled to receive fractional shares as a result of the reverse stock split will be entitled to a cash payment in lieu thereof at a price equal to the fraction to which the stockholder would otherwise be entitled multiplied by the closing sales price per share of the common stock (as adjusted to give effect to the reverse stock split) on The Nasdaq Capital Market today, the last trading day immediately preceding the effective time of the reverse stock split.

XORTX Announces Completion of Screening and Enrollment in Bridging Pharmacokinetics Study

Retrieved on: 
Monday, November 28, 2022
Knowledge, US Foods, COVID-19, Unitary state, Incidence, Diagnosis, Kidney disease, Pharmacokinetics, Food, Kidney, Polycystic kidney disease, Uric acid, Health Canada, EMA, Cyst, European Medicines Agency, Safety, Therapy, Oxipurinol, Autosome, Chronic pain, TSX Venture Exchange, Patient, Analysis, Coronavirus, XRX, Xanthine oxidase, International, News, Health, Absorption, Form, Quality of life, Fibrosis, Consultant, Diabetes, Study, Clinical trial, FDA, Metabolism, XO, Pharmaceutical industry, ADPKD

The Company anticipates completion of dosing in the XRX-OXY-101 clinical trial in the coming weeks and additional announcements of topline results of the final two parts of the Study in the near future.

Key Points: 
  • The Company anticipates completion of dosing in the XRX-OXY-101 clinical trial in the coming weeks and additional announcements of topline results of the final two parts of the Study in the near future.
  • The key data emerging from this Study will be essential to our pharmacokinetic modeling and selection of a safe dose for individuals in the planned XRX-OXY-301 phase 3 clinical trial.
  • Oxypurinol is a purine based xanthine oxidase inhibitor with important pharmacologic characteristics ideal for administration to individuals with ADPKD.
  • At XORTX, we are dedicated to developing medications to improve the quality of life and future health of patients.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Olo, Centessa, PayPal, and Opendoor and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, November 28, 2022
Observation, Restaurant, DoorDash, Tripura Merger Agreement, A1AT, Bloomberg, Risk, Autosome, Class Action, Defendant, Class, Registration statement, BID, ADS, PayPal, P.C, Farm, NNA, Patient, Prospectus, Register, CNTA, SCH, Churn, PYPL, Growth, Polycystic kidney disease, DNA, Partnership, News, NYSE, Form, Fraud, Initial, Liver, Acquisition, AATD, Complaint, IPO, AE, Holding company, Food delivery, Risk management, Audit, Medical device, Security (finance), Animal, Renewable energy, Cryptocurrency, Online shopping, Opendoor, Subway, Algorithm, Mergers and acquisitions

Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.

Key Points: 
  • Throughout the Class Period, Olo touted the growth of its active locations, with Subway accounting for approximately 20% of those locations.
  • By the first quarter of 2022, the Companys active locations had grown to approximately 82,000 a 19% increase over the prior year.
  • For more information on the Opendoor class action go to: https://bespc.com/cases/OPEN
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.